1. Segawa T, Takebayashi H, Kakehi Y, Yoshida O, Narumiya S and Kakizuka A (1998) Prostate-specific amplification of expanded polyglutamine expression: a novel approach for cancer gene therapy. Cancer Res. 58: 2282–2287
2. Huang P, Feng L, Oldham EA, Keating MJ and Plunkett W (2000) Superoxide dismutase as a target for the selective killing of cancer cells. Nature 407: 390–395
3. Shen ZX, Chen GQ, Ni JH, Li XS, Xiong SM, Qiu QY, Zhu J, Tang W, Sun GL, Yang KQ, Chen Y, Zhou L, Fang ZW, Wang YT, Ma J, Zhang P, Zhang TD, Chen SJ, Chen Z and Wang ZY (1997) Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients. Blood 89: 3354–3360
4. Maeda H, Hori S, Nishitoh H, Ichijo H, Ogawa O, Kakehi Y and Kakizuka A (2001) Tumor growth inhibition by arsenic trioxide in the orthotopic metastasis model of androgen-independent prostate cancer. Cancer Res. 61: 5432–5440
5. Chen GQ, Shi XG, Tang W, Xiong SM, Zhu J, Cai X, Han ZG, Ni JH, Shi GY, Jia PM, Liu MM, He KL, Niu C, Ma J, Zhang P, Zhang TD, Paul P, Naoe T, Kitamura K, Miller W, Waxman S, Wang ZY, de The H, Chen SJ and Chen Z (1997) Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): I. As2O3 exerts dose-dependent dual effects on APL cells. Blood 89: 3345–3353